{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:03:09Z","timestamp":1783980189640,"version":"3.55.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100029643","name":"Collaboratory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100029643","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.dadr.2026.100413","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T19:14:07Z","timestamp":1769714047000},"page":"100413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Barriers and facilitators to methadone dispensing for opioid use disorder in community pharmacies: A scoping review"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8044-9838","authenticated-orcid":false,"given":"Caroline","family":"Shubel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ava","family":"Nunnery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Marley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayla","family":"Ostrach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delesha M.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dadr.2026.100413_bib1","series-title":"Increasing the Number of OTPs and Patients in the United States","author":"AATOD","year":"2022"},{"key":"10.1016\/j.dadr.2026.100413_bib2","unstructured":"AATOD, 2023. The Modernizing Opioid Treatment Access (MOTA) Act: Fact-Checking Sheet. In."},{"key":"10.1016\/j.dadr.2026.100413_bib3","article-title":"Community pharmacy working conditions: Is stress impacting patient care?","volume":"20","author":"Alvarez","year":"2025","journal-title":"Explor Res Clin. Soc. Pharm."},{"issue":"3","key":"10.1016\/j.dadr.2026.100413_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1211\/ijpp.15.3.0005","article-title":"Enhanced pharmacy services, barriers and facilitators in Australia's community pharmacies: Australia's National Pharmacy Database Project","volume":"15","author":"Berbatis","year":"2007","journal-title":"Int. J. Pharm. Pract."},{"key":"10.1016\/j.dadr.2026.100413_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1141093","article-title":"Barriers to opioid use disorder treatment: A comparison of self-reported information from social media with barriers found in literature","volume":"11","author":"Bremer","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.dadr.2026.100413_bib6","article-title":"Opioid treatment program prescribing of methadone with community pharmacy dispensing: Pilot study of feasibility and acceptability","volume":"3","author":"Brooner","year":"2022","journal-title":"Drug Alcohol Depend. Rep."},{"issue":"5","key":"10.1016\/j.dadr.2026.100413_bib7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/dar.12209","article-title":"Senior nurses' perspectives on the transfer of opioid substitution treatment clients from clinics to community pharmacy","volume":"34","author":"Bui","year":"2015","journal-title":"Drug Alcohol Rev."},{"issue":"6","key":"10.1016\/j.dadr.2026.100413_bib8","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s11606-018-4801-3","article-title":"Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction","volume":"34","author":"Calcaterra","year":"2019","journal-title":"J. Gen. Intern Med"},{"key":"10.1016\/j.dadr.2026.100413_bib9","article-title":"Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone","volume":"6","author":"Carl","year":"2023","journal-title":"Drug Alcohol Depend. Rep."},{"issue":"1","key":"10.1016\/j.dadr.2026.100413_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/ADM.0000000000001244","article-title":"A Brief Online Training to Address Pharmacists' Willingness to Dispense Buprenorphine","volume":"18","author":"Carpenter","year":"2024","journal-title":"J. Addict. Med"},{"key":"10.1016\/j.dadr.2026.100413_bib11","article-title":"Reducing Stigma Within Pharmacy Opioid Agonist Treatment Encounters","author":"Caruana","year":"2024","journal-title":"Stigma Health"},{"key":"10.1016\/j.dadr.2026.100413_bib12","article-title":"Opioid agonist treatment and trust in the community pharmacy setting: a qualitative study of perceptions and experiences","author":"Caruana","year":"2024","journal-title":"Drugs Educ. Prev. Policy"},{"issue":"4","key":"10.1016\/j.dadr.2026.100413_bib13","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/dar.12032","article-title":"Factors influencing pharmacy services in opioid substitution treatment","volume":"32","author":"Chaar","year":"2013","journal-title":"Drug Alcohol Rev."},{"issue":"3","key":"10.1016\/j.dadr.2026.100413_bib14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.sapharm.2022.09.009","article-title":"Informing a collaborative-care model for delivering medication assisted treatment for opioid dependence (MATOD): An analysis of pharmacist, prescriber and patient perceptions","volume":"19","author":"Cheetham","year":"2023","journal-title":"Res Soc. Adm. Pharm."},{"key":"10.1016\/j.dadr.2026.100413_bib15","unstructured":"CMS,Opioid Treatment Programs (OTP). CMS.gov. Retrieved April 11th 2025, from https:\/\/www.cms.gov\/medicare\/payment\/opioid-treatment-program."},{"issue":"1","key":"10.1016\/j.dadr.2026.100413_bib16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.japh.2022.08.027","article-title":"Understanding the role of community pharmacies in current medication for opioid use disorder care practices","volume":"63","author":"Comanici","year":"2023","journal-title":"J. Am. Pharm. Assoc. (2003)"},{"key":"10.1016\/j.dadr.2026.100413_bib17","author":"Covidence","year":"2025","journal-title":"Covidence Syst. Rev. Softw."},{"issue":"6","key":"10.1016\/j.dadr.2026.100413_bib18","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies","volume":"10","author":"Degenhardt","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"25","key":"10.1016\/j.dadr.2026.100413_bib19","doi-asserted-by":"crossref","first-page":"567","DOI":"10.15585\/mmwr.mm7325a1","article-title":"Treatment for Opioid Use Disorder: Population Estimates \u2014 United States, 2022","volume":"73","author":"Dowell","year":"2024","journal-title":"Mmwr. Morb. Mortal. Wkly. Rep."},{"issue":"1","key":"10.1016\/j.dadr.2026.100413_bib20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13011-021-00374-x","article-title":"Qualitative assessment of patients' perspectives and needs from community pharmacists in substance use disorder management","volume":"16","author":"Fatani","year":"2021","journal-title":"Subst. Abus. Treat. Prev. Policy"},{"issue":"1","key":"10.1016\/j.dadr.2026.100413_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/jrh.12264","article-title":"Perceived Barriers and Facilitators to Providing Methadone Maintenance Treatment Among Rural Community Pharmacists in Southwestern Ontario","volume":"34","author":"Fonseca","year":"2018","journal-title":"J. Rural Health"},{"issue":"1","key":"10.1016\/j.dadr.2026.100413_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12954-021-00535-y","article-title":"\"It's like 'liquid handcuffs\": The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients' lives","volume":"18","author":"Frank","year":"2021","journal-title":"Harm Reduct. J."},{"issue":"3","key":"10.1016\/j.dadr.2026.100413_bib23","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.sapharm.2013.07.006","article-title":"Contested space in the pharmacy: public attitudes to pharmacy harm reduction services in the West of Scotland","volume":"10","author":"Gidman","year":"2014","journal-title":"Res Soc. Adm. Pharm."},{"key":"10.1016\/j.dadr.2026.100413_bib24","author":"Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence","year":"2009","journal-title":"World Health Organ."},{"issue":"3","key":"10.1016\/j.dadr.2026.100413_bib25","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/humrep\/dev334","article-title":"Qualitative research methods: when to use them and how to judge them","volume":"31","author":"Hammarberg","year":"2016","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.dadr.2026.100413_bib26","article-title":"Methadone Take-Home Policies and Associated Mortality: Permitting versus Non-Permitting States","volume":"18","author":"Harris","year":"2024","journal-title":"Subst. Use"},{"issue":"4","key":"10.1016\/j.dadr.2026.100413_bib27","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/29767342241262115","article-title":"U.S. Healthcare Workers' Perspective of Outpatient Provision of Methadone: A Scoping Review","volume":"45","author":"Hernandez","year":"2024","journal-title":"Subst. Use Addctn J."},{"issue":"3","key":"10.1016\/j.dadr.2026.100413_bib28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/cjrm.cjrm_56_23","article-title":"I'm on the coast and I'm on methadone': A qualitative study examining access to opioid agonist treatment in rural and coastal British Columbia","volume":"29","author":"Hodgson","year":"2024","journal-title":"Can. J. Rural Med"},{"key":"10.1016\/j.dadr.2026.100413_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211022994","article-title":"U.S. student pharmacist perceptions of the pharmacist's role in methadone for opioid use disorder: A qualitative study","volume":"9","author":"Hohmeier","year":"2021","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.dadr.2026.100413_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108534","article-title":"Expanding access to methadone treatment in Ohio through federally qualified health centers and a chain pharmacy: A geospatial modeling analysis","volume":"220","author":"Iloglu","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"6","key":"10.1016\/j.dadr.2026.100413_bib31","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.sapharm.2012.01.001","article-title":"Dealing with aggressive methadone patients in community pharmacy: a critical incident study","volume":"8","author":"Irwin","year":"2012","journal-title":"Res Soc. Adm. Pharm."},{"issue":"5","key":"10.1016\/j.dadr.2026.100413_bib32","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.sapharm.2024.02.001","article-title":"\"I go out of my way to give them an extra smile now:\" A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials","volume":"20","author":"Irwin","year":"2024","journal-title":"Res Soc. Adm. Pharm."},{"issue":"4","key":"10.1016\/j.dadr.2026.100413_bib33","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/08897077231203849","article-title":"Research priorities for expansion of opioid use disorder treatment in the community pharmacy","volume":"44","author":"Jarrett","year":"2023","journal-title":"Subst. Abus"},{"key":"10.1016\/j.dadr.2026.100413_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.107968","article-title":"Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study","volume":"211","author":"Joudrey","year":"2020","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.dadr.2026.100413_bib35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/08897077.2021.1975344","article-title":"Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: a National Institute on Drug Abuse Center for Clinical Trials Network Task Force report","volume":"42","author":"Joudrey","year":"2021","journal-title":"Subst. Abus"},{"issue":"11","key":"10.1016\/j.dadr.2026.100413_bib36","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jamapsychiatry.2020.1624","article-title":"Comparison of driving times to opioid treatment programs and pharmacies in the US","volume":"77","author":"Kleinman","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.dadr.2026.100413_bib37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10389-016-0714-y","article-title":"Community pharmacy-based opiate substitution treatment and related health services: a study of 508 patients and 111 pharmacies","volume":"24","author":"Laird","year":"2016","journal-title":"J. Public Health (Ger. )"},{"issue":"2","key":"10.1016\/j.dadr.2026.100413_bib38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/09595230410001704181","article-title":"Pharmacy customers' views and experiences of using pharmacies which provide drug misuse services","volume":"23","author":"Lawrie","year":"2004","journal-title":"Drug Alcohol Rev."},{"issue":"1","key":"10.1016\/j.dadr.2026.100413_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/09595230701710852","article-title":"Dispensing opioid substitution treatment: practices, attitudes and intentions of community-based pharmacists","volume":"27","author":"Lawrinson","year":"2008","journal-title":"Drug Alcohol Rev."},{"issue":"8","key":"10.1016\/j.dadr.2026.100413_bib40","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.sapharm.2019.02.003","article-title":"Perspectives on privacy in the pharmacy: The views of opioid substitution treatment clients","volume":"15","author":"Le","year":"2019","journal-title":"Res Soc. Adm. Pharm."},{"issue":"1","key":"10.1016\/j.dadr.2026.100413_bib41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1211\/ijpp.14.1.0008","article-title":"Exploring the dissonance between business and public health policy: Pharmacy and the provision of opioid pharmacotherapies and clean needles in rural settings","volume":"14","author":"Le","year":"2006","journal-title":"Int. J. Pharm. Pract."},{"issue":"3","key":"10.1016\/j.dadr.2026.100413_bib42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1211\/ijpp.16.3.0004","article-title":"South Australian rural community pharmacists and the provision of methadone, buprenorphine and injecting equipment","volume":"16","author":"Le","year":"2008","journal-title":"Int. J. Pharm. Pract."},{"issue":"3","key":"10.1016\/j.dadr.2026.100413_bib43","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0955-3959(00)00047-5","article-title":"Involvement of community pharmacists in the care of drug misusers: pharmacy-based supervision of methadone consumption","volume":"11","author":"Luger","year":"2000","journal-title":"Int J. Drug Policy"},{"issue":"4","key":"10.1016\/j.dadr.2026.100413_bib44","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1071\/HC20108","article-title":"We're just seen as people that give out the methadone\u2026': exploring the role of community pharmacists in the opioid substitution treatment team","volume":"12","author":"Lukey","year":"2020","journal-title":"J. Prim. Health Care"},{"issue":"2","key":"10.1016\/j.dadr.2026.100413_bib45","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11524-011-9651-9","article-title":"Injection drug users' perspectives on placing HIV prevention and other clinical services in pharmacy settings","volume":"89","author":"Lutnick","year":"2012","journal-title":"J. Urban Health"},{"issue":"12","key":"10.1016\/j.dadr.2026.100413_bib46","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1192\/pb.bp.109.028951","article-title":"Stigmatised attitudes in independent pharmacies associated with discrimination towards individuals with opioid dependence","volume":"34","author":"Luty","year":"2010","journal-title":"Psychiatrist"},{"issue":"5","key":"10.1016\/j.dadr.2026.100413_bib47","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14659890410001711724","article-title":"A comparison of community pharmacy methadone services between Dublin and Glasgow: (1) Extent of service provision in 1997\/1998 and views of pharmacists on existing provision and future service developments","volume":"9","author":"Mackie","year":"2004","journal-title":"J. Subst. Use"},{"issue":"2","key":"10.1016\/j.dadr.2026.100413_bib48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/ACM.0000000000005467","article-title":"Stigma Against Patients With Substance Use Disorders Among Health Care Professionals and Trainees and Stigma-Reducing Interventions: A Systematic Review","volume":"99","author":"Magnan","year":"2024","journal-title":"Acad. Med"},{"issue":"6992","key":"10.1016\/j.dadr.2026.100413_bib49","first-page":"639","article-title":"Privacy and stigma in the pharmacy: Illicit drug users' perspectives and implications for pharmacy practice","volume":"260","author":"Matheson","year":"1998","journal-title":"Pharm. J."},{"issue":"9","key":"10.1016\/j.dadr.2026.100413_bib50","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1046\/j.1360-0443.1999.94913497.x","article-title":"Attitudinal factors associated with community pharmacists' involvement in services for drug misusers","volume":"94","author":"Matheson","year":"1999","journal-title":"Addiction"},{"issue":"11","key":"10.1016\/j.dadr.2026.100413_bib51","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1046\/j.1360-0443.2002.00241.x","article-title":"Community pharmacy services for drug misusers in Scotland: what difference does 5 years make?","volume":"97","author":"Matheson","year":"2002","journal-title":"Addiction"},{"key":"10.1016\/j.dadr.2026.100413_bib52","unstructured":"2023. Modernizing Opioid Treatment Access Act S 644 Congress."},{"issue":"9","key":"10.1016\/j.dadr.2026.100413_bib53","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1176\/appi.ajp.2021.20101548","article-title":"Office-based methadone treatment for opioid use disorder and pharmacy dispensing: a scoping review","volume":"178","author":"McCarty","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.dadr.2026.100413_bib54","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/09687630600790153","article-title":"New Zealand community pharmacist attitudes toward opioid-dependent clients","volume":"13","author":"McCormick","year":"2006","journal-title":"Drugs Educ. Prev. Policy"},{"issue":"3","key":"10.1016\/j.dadr.2026.100413_bib55","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"Int J. Evid. Based Health"},{"issue":"4","key":"10.1016\/j.dadr.2026.100413_bib56","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/08897077.2019.1616349","article-title":"Pharmacists' attitudes toward dispensing naloxone and medications for opioid use disorder: a scoping review of the literature","volume":"40","author":"Muzyk","year":"2019","journal-title":"Subst. Abus"},{"key":"10.1016\/j.dadr.2026.100413_bib57","doi-asserted-by":"crossref","unstructured":"Nguyen, C.M., Kubiak*, G., Dixit*, N., Young, S.A., Hayes, J.R.Evaluating Barriers to Opioid Use Disorder Treatment From Patients\u2019 Perspectives. 2024https:\/\/doi.org\/10.22454\/PRiMER.2024.458349.","DOI":"10.22454\/PRiMER.2024.458349"},{"key":"10.1016\/j.dadr.2026.100413_bib58","author":"NHLBI","year":"2013","journal-title":"Study Qual. Assess. Tools"},{"key":"10.1016\/j.dadr.2026.100413_bib59","author":"NICE","year":"2012","journal-title":"Append. H. Qual. Apprais. Checkl. Qual. Stud."},{"issue":"8","key":"10.1016\/j.dadr.2026.100413_bib60","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.sapharm.2019.11.007","article-title":"Continuation of opioid replacement program delivery in the aftermath of cyclones in Queensland, Australia: A qualitative exploration of the perspectives of pharmacists and opioid replacement therapy staff","volume":"16","author":"O'Dwyer","year":"2020","journal-title":"Res Soc. Adm. Pharm."},{"issue":"1","key":"10.1016\/j.dadr.2026.100413_bib61","doi-asserted-by":"crossref","DOI":"10.1186\/s13722-022-00316-3","article-title":"Cumulative barriers to retention in methadone treatment among adults from rural and small urban communities","volume":"17","author":"Pasman","year":"2022","journal-title":"Addict. Sci. Clin. Pract."},{"issue":"6","key":"10.1016\/j.dadr.2026.100413_bib62","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/dar.12979","article-title":"The lived experience of Australian opioid replacement therapy recipients in a community-based program in regional Victoria","volume":"38","author":"Patil Vishwanath","year":"2019","journal-title":"Drug Alcohol Rev."},{"issue":"5","key":"10.1016\/j.dadr.2026.100413_bib63","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2710.2007.00857.x","article-title":"Harm minimization strategies: opinions of health professionals in rural and remote Australia","volume":"32","author":"Peterson","year":"2007","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.dadr.2026.100413_bib64","author":"Pew","year":"2023","journal-title":"Aust. Prim. Care Pharm. Deliv. Methad."},{"key":"10.1016\/j.dadr.2026.100413_bib65","author":"Pew","year":"2023","journal-title":"Can. Lifesav. Methad. Is. Available a Var. Treat. Settings"},{"key":"10.1016\/j.dadr.2026.100413_bib66","author":"Pew","year":"2023","journal-title":"How Can. Patients Access Methad. Other Ctries."},{"issue":"4","key":"10.1016\/j.dadr.2026.100413_bib67","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/pubmed\/fdw138","article-title":"Standing Outside the Junkie Door'-service users' experiences of using community pharmacies to access treatment for opioid dependency","volume":"39","author":"Radley","year":"2017","journal-title":"J. Public Health (Oxf. )"},{"issue":"2","key":"10.1016\/j.dadr.2026.100413_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2024.102319","article-title":"Community pharmacy-based buprenorphine programs and pharmacists' roles, knowledge, attitudes, and barriers to providing buprenorphine-related services: A systematic review","volume":"65","author":"Rawal","year":"2025","journal-title":"J. Am. Pharm. Assoc."},{"issue":"1","key":"10.1016\/j.dadr.2026.100413_bib69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/14659890600774789","article-title":"What's the problem? Why do some pharmacists provide services to drug users and others won't?","volume":"12","author":"Roberts","year":"2007","journal-title":"J. Subst. Use"},{"issue":"3","key":"10.1016\/j.dadr.2026.100413_bib70","first-page":"110","article-title":"Service provision to opiate misusers from pharmacies - An exploratory study","volume":"20","author":"Rosenblom","year":"2003","journal-title":"J. Soc. Adm. Pharm."},{"issue":"8","key":"10.1016\/j.dadr.2026.100413_bib71","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/add.16180","article-title":"Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety","volume":"118","author":"Saloner","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.dadr.2026.100413_bib72","unstructured":"SAMHSA . Retrieved 05\/09\/25 from https:\/\/www.samhsa.gov\/substance-use\/treatment\/opioid-treatment-program\/become-otpBecome an Opioid Treatment Program (OTP)."},{"key":"10.1016\/j.dadr.2026.100413_bib73","series-title":"PEP23-07-01-006, NSDUH Series H-58). SAMSHA","article-title":"Key substance use and mental health indicators in the United States: Results from the 2022 National Survey on Drug Use and Health (HHS Publication No","author":"SAMHSA","year":"2023"},{"key":"10.1016\/j.dadr.2026.100413_bib74","series-title":"42 CFR Part 8 Final Rule","author":"SAMHSA","year":"2024"},{"issue":"1","key":"10.1016\/j.dadr.2026.100413_bib75","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000095815","article-title":"The role of pharmacies in the care of drug users: what has changed in ten years","volume":"13","author":"Samitca","year":"2007","journal-title":"case a Swiss Reg. Eur. Addict. Res"},{"key":"10.1016\/j.dadr.2026.100413_bib76","author":"Shubel","year":"2025","journal-title":"Scoping Rev. Protoc. Pharm. Based Methad. Dispens. (Version 1) UNC Dataverse"},{"issue":"S2","key":"10.1016\/j.dadr.2026.100413_bib77","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.2105\/AJPH.2021.306665","article-title":"The methadone manifesto: treatment experiences and policy recommendations from methadone patient activists","volume":"112","author":"Simon","year":"2022","journal-title":"Am. J. Public Health"},{"issue":"3","key":"10.1016\/j.dadr.2026.100413_bib78","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jppr.1202","article-title":"Knowledge and attitudes of final year pharmacy students toward opioid substitution therapy","volume":"46","author":"Snoswell","year":"2016","journal-title":"J. Pharm. Pract. Res."},{"key":"10.1016\/j.dadr.2026.100413_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108031","article-title":"One year of methadone maintenance treatment in a fentanyl endemic area: safety, repeated exposure, retention, and remission","volume":"115","author":"Stone","year":"2020","journal-title":"J. Subst. Abus. Treat."},{"issue":"5","key":"10.1016\/j.dadr.2026.100413_bib80","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1080\/09687637.2021.1936457","article-title":"Professional education to reduce provider stigma toward harm reduction and pharmacotherapy","volume":"29","author":"Sulzer","year":"2022","journal-title":"Drugs Education Prevention Policy"},{"issue":"7","key":"10.1016\/j.dadr.2026.100413_bib81","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern Med"},{"issue":"3","key":"10.1016\/j.dadr.2026.100413_bib82","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00132576-200302030-00005","article-title":"Office based methadone treatment: A role for community pharmacists","volume":"2","author":"Tuchman","year":"2003","journal-title":"Addict. Disord. their Treat."},{"issue":"1","key":"10.1016\/j.dadr.2026.100413_bib83","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.adt.0000149396.93300.01","article-title":"Office-based Opioid Treatment (OBOT): Practitioner's knowledge, attitudes, and expectations in New Mexico","volume":"4","author":"Tuchman","year":"2005","journal-title":"Addict. Disord. their Treat."},{"issue":"6","key":"10.1016\/j.dadr.2026.100413_bib84","doi-asserted-by":"crossref","first-page":"668","DOI":"10.30773\/pi.2025.0039","article-title":"A Global Perspective on Incidence and Regional Trends of Opioid Use Disorders From 1990 to 2021","volume":"22","author":"Tuo","year":"2025","journal-title":"Psychiatry Invest."},{"key":"10.1016\/j.dadr.2026.100413_bib85","series-title":"World Drug Report","author":"UNODC","year":"2023"},{"issue":"2","key":"10.1016\/j.dadr.2026.100413_bib86","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"10.1016\/j.dadr.2026.100413_bib87","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1360-0443.2009.02774.x","article-title":"Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia","volume":"105","author":"Winstock","year":"2010","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.dadr.2026.100413_bib88","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/add.15641","article-title":"Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial","volume":"117","author":"Wu","year":"2022","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.dadr.2026.100413_bib89","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13722-023-00399-6","article-title":"Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S","volume":"18","author":"Wu","year":"2023","journal-title":"Addict. Sci. Clin. Pr."},{"issue":"1","key":"10.1016\/j.dadr.2026.100413_bib90","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13011-023-00563-w","article-title":"Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff","volume":"18","author":"Wu","year":"2023","journal-title":"Subst. Abus. Treat. Prev. Policy"},{"issue":"2","key":"10.1016\/j.dadr.2026.100413_bib91","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s11096-019-00790-x","article-title":"Community pharmacists' role in preventing opioid substitution therapy-related deaths: a qualitative investigation into current UK practice","volume":"41","author":"Yadav","year":"2019","journal-title":"Int J. Clin. Pharm."}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724626000065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724626000065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T02:25:29Z","timestamp":1774059929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724626000065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":91,"alternative-id":["S2772724626000065"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2026.100413","relation":{},"ISSN":["2772-7246"],"issn-type":[{"value":"2772-7246","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barriers and facilitators to methadone dispensing for opioid use disorder in community pharmacies: A scoping review","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2026.100413","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100413"}}